

# Living related Donor Liver Transplantation

(LDLT)



## for Hepatocellular Carcinoma


By

Mohamed Abd ELWahab

**GASTROENTEROLOGY CENTER**

**Mansoura University Egypt**







# Liver Resection in Compensated Cirrhosis

## “Why Not Transplantation?”

---



- **Immunosuppressive therapy may accelerate the growth rate of recurrent HCC**
  - **Mean tumour doubling times (TDT)**
    - **after transplantation is 40 days**
    - **after resection is 275 days**
- (Yokoyama et al, 1991)*
- **Sever organ shortage**
  - **Doubtful Diagnosis (regenerating nodules)**




# Resection depends on.




- ✓ Size of the tumor
- ✓ Underlying liver pathology.
- ✓ Hepatocyte function.
- ✓ Associated portal hypertension

HCC with large mass 30 cm





# Survival after hepatic resection in cirrhotic liver



R After R H (3 years)





# Out come of resection in Egypt

---

- **80%** of HCC developed in cirrhotic liver
- **15%** suitable for resection
- **22%** 5 year survival
- **32%** Recurrence at 18 months
- **26 %** post operative complications
  - **Bleeding**
  - **Infection**
  - **Hepatic cell failure**



# LDLT for HCC in Cirrhotics



## “Why Not Resection?”

- **HCC is associated with cirrhosis in 70-90% of cases; underlying cirrhosis is a pre-malignant condition**
- **LTX treats both the cirrhosis & the cancer**
- **Poor liver reserve limits tolerability of resection**
- **Multi-focal HCC is common findings at transplantation**
  - ✓ **HCC < 5cm: 39% multifocal**
  - ✓ **HCC > 5cm: 79% multifocal**
- **Often underestimated by current imaging**
- **Resection has High Recurrence Rates: (50-90%) by 5 yrs**
- **LTx has better Survival Rates without recurrence for small uninodular or binodular tumors (83% vs. 18%) by 5 yrs**






# Liver Transplantation for HCC

## “Patient Selection”

---




### Milan's Criteria



Single tumor  $\leq 5$  cm

OR



$\leq 3$  lesions, each lesion  $\leq 3$  cm

- **No Macro-Vascular Invasion**
- **No Extra-hepatic Spread**

*(Mazzaferro et al, 1994)*




# Liver Transplantation for HCC

## “Patient Selection”




### UCSF Criteria (Expanded Criteria)



Single tumor  $\leq 6.5$  cm

OR



$\leq 3$  lesions, each lesion  $\leq 4.5$  cm  
+ Total tumor burden  $\leq 8$  cm

+

No Macro-Vascular Invasion and No Extra-hepatic Spread



## **Expanded Criteria for Hepatocellular Carcinoma and Liver Transplantation**

G. Moray, F. Karakayali, U. Yilmaz, F. Ozcay, B. Bilezikci, and M. Haberal

Patients with HCC and a cirrhotic liver but without extrahepatic disease should be candidates for liver transplantation whenever possible, Tumor size and the number of the tumor cannot be the sole criteria to abandon liver transplantation, the tumor cell burden in the circulation is more important than the local extent of the tumor. we will recommend liver transplantation regardless of tumor size and number.

**(Moray, karakayali, yilmaz et al-2007)**



# Tumor characteristics predictive of recurrence after liver transplantation

---




- ❑ Large tumour size ( $> 5$  cm)
- ❑ Multiple lesions ( $> 3$  lesions)
- ❑ Bilobar involvement
- ❑ Tumour ulcerating through the capsule
- ❑ Macro-vascular invasion
- ❑ Absence of pseudocapsule
- ❑ Lymph node involvement
- ❑ Extra hepatic spread
- ❑ Micro-vascular invasion
- ❑ Poorly differentiated HCC

*(Yao et al., 2002 - Hugentobler et al, France)*



# LIVER TRANSPLANTATION IN EGYPT







# IN EGYPT



- Liver resection and local ablation are regarded as potentially curative treatments, for HCC in Egypt up to 2001
- Deceased donor Liver transplantation up till now not allowed in Egypt
- In 10 centers LDLT started since 2001





# LDLT IN EGYPT




- Recent advances in adult LDLT using a right lobe graft have overcome the barrier of deceased donor and produce a drastic change in the role of transplantation surgery for HCC.
- Can potentially provide an essentially unlimited source of liver grafts for a planned transplant operation as soon as the diagnosis of HCC is made.



# LDLT IN EGYPT



- A long waiting period can be much lessened and the possibility of tumor progression eliminated
- Live donor graft is a dedicated gift that is directed to a particular recipient



Father





Son





# Mansoura Experience LDLT in HCC





# No of patient referred for Transplantation Mansoura Egypt



**800 ( 5Y )**

Indication	No	%
➤ Liver Cirrhosis	490	61
➤ HCC	250	31
➤ Other causes	60	8



# Final Out Come Of 800 Case

---

	No	%
<b>Transplanted</b>	93	12
<b>Waiting</b>	46	3.5
<b>Non</b>	665	84



# Causes Of Non Transplantation


## 665 cases ( 84%)



Transplantation	No	%
● Early cirrhosis	200	29
● Advanced HCC	140	17
● No Donor	75	10
● PV thrombosis	50	4.7
● NO information	120	14
● Death	50	8.5



# Number Of LDLT Per year (93 cases )





## LDLT Mansoura experience (93 case )



<b>Mean age</b>	<b>46.67 Y</b>
<b>Indication</b>	
– <b>Cirrhosis</b>	<b>53</b>
– <b>HCC</b>	<b>35</b>
– <b>Budd chiari</b>	<b>2</b>
– <b>Auto immune</b>	<b>3</b>



# Experience with LDLT for HCC at: Gastroenterology Center Mansoura University




**GEC 1990 – 100 beds - Tertiary Referral  
Research center**



**LDLT program was started in April 2004  
Prof Mohamed Abdel wahab**



# 35 LDLT Transplantation for HCC








# 250 HCC referred for transplantation from 2004 : 2009



	No	%
Advanced HCC	117	47
<b>Transplanted</b>	<b>37</b>	<b>15</b>
Distant Metastasis	35	13.5
Death	20	8
PV thrombosis	18	7
No donor	17	6.5
NO information	16	6




# Distribution of transplanted cases for HCC





# Yearly transplanted cases ( HCC , cirrhosis )



Mansoura Egypt




# Management of HCC Patient While on the Waiting List



## Regular Close Follow-up

- **Clinical**
- **Biochemical (AFP)**
- **Radiological (CT- MRI)**
- **Intervention**
  - **RFA or PEI**
  - **TACE**
  - **Resection??**
- **De-Listing**








# Management While on the Waiting List



- TACE 4 patient
- Radiofrequency 2 patient





# 39 Patients Explored With HCC For LDLT



35 transplanted

4 exploration only

- + Diaphragmatic infiltration
- + Pelvic nodule after radiofrequency
- + Positive L.N metastasis
- + Suprarenal infiltration






# Diagnosis



**Incidental  
diagnosis**



**Preoperative  
diagnosis**



## LDLT for HCC (35)form 2004 : 2010

	NO
<b>Age M/SD</b>	<b>50Y</b>
<b>Sex M/F</b>	<b>5/30</b>
<b>Causes of cirrhosis</b>	
– HCV	<b>33</b>
– HBV	<b>2</b>
<b>Child classification</b>	
–A	<b>5</b>
–B	<b>15</b>
–C	<b>17</b>
<b>Meld</b>	
–M	<b>21.5</b>
–Rang	<b>12-35</b>
–SD	<b>5.2</b>










# LDLT for HCC (35) Form 2004 : 2009



	NO
<b>Site of the tumor</b>	
-Right	18
-Left	5
-Multifocal	12
<b>Number</b>	
-Single	23
- Multiple II	8
III	3
VI	1
V	2
<b>Size</b>	
•<6	31
•>6	3
<b>AFP</b>	
-M	41.6
-S.D	106.45







# Donor



● Total No of Potential Donors evaluated	140	
● No of accepted donor	35	26 %
● Male / Female	26/ 9	75/25 %
● Age	M 27.6 ± 7.4	18:45
● Wt.	M 79 .5 ± 9.7	62:105
● Height	M 171 ± 7.5 27 ±	150:187
● BMI	2.9	20.8 :33.4



# Donor Relationships (37)

---


<b>Son</b>	<b>11</b>
<b>Nephew</b>	<b>6</b>
<b>Wife</b>	<b>4</b>
<b>Cousin</b>	<b>2</b>
<b>The in laws</b>	<b>3</b>
<b>Brother</b>	<b>2</b>
<b>Daughter</b>	<b>2</b>
<b>Sister</b>	<b>1</b>
<b>Niece</b>	<b>2</b>
<b>Mother</b>	<b>1</b>





# Venous Outflow Reconstruction




Type	No
Rt hepatic alone	22
Rt hepatic + posterior HV	5
Rt hepatic + seg V	3
Rt hepatic + seg VIII	3
Rt hepatic + posterior HV ,V,VIII	6









# RHV + Mach.+ V + VIII












# Biliary anastomosis



<b>Single</b>	۲۰	
<b>Double</b>	۱۴	
<b>Triple</b>	۳	



# Biliary + vascular complications



Type	No	Management
Leak	۲	Conservative
Stricture	۲	Stent, surg
PV stenosis	۱	Dilatation



# Bile Duct Complications

## 4 ( 37)



**Bile duct stenosis**

**2**



**Bile leak with biloma**

**2**





# Complication after LDLT (35)



- **Biliary leak** 2
- **Biliary stricture** 2
- **Graft failure** 1
- **Internal haemorrhage** 2
- **Tumor recurrence** 1
- **Cardio pulmonary** 2
- **Small for size syndrome** 2



# Mortality after LDLT for HCC 4/35 (12 %)



	<b>Time</b>	<b>Causes</b>
<b>1</b>	<b>2 W</b>	<b>Brain stem infarction</b>
<b>2</b>	<b>3W</b>	<b>Graft failure</b>
<b>3</b>	<b>3 M</b>	<b>Abdominal infection &amp; renal failure</b>
<b>4</b>	<b>12 M</b>	<b>Recurrence</b>



# Recurrence



**Only one case (12 months)**

**with multiple HCC more  
than 8 cm with micro  
vascular invasion.**



# Comparison between resection & LDLT for HCC (2004 -2009 )



- **From 2004 – 2009**
- **140 cases with HCC treated by resection**
- **78 cases the tumor was less than 6 cm**
- **Comparison between resection & LDLT**





# Comparison between resection & LDLT for HCC (2004 -2009 )



	Resection	LDLT
<b>NO</b>	<b>78</b>	<b>35</b>
<b>AGE</b>		
-M	<b>54.9</b>	<b>50Y</b>
-S.D	<b>(±9.3)</b>	
<b>SEX</b>		
-M/F	<b>64/14</b>	<b>5/30</b>
<b>MELD</b>		
-M	<b>9.3</b>	<b>21.5</b>
-S.D	<b>(±2.8)</b>	<b>5.2</b>
<b>CHILD</b>		
-A	<b>7</b>	<b>5</b>
-B	<b>8</b>	<b>13</b>
-C	<b>0</b>	<b>17</b>



# Comparison between resection & LDLT for HCC (2004 -2009 )



	Resection	LDLT
<b>NO</b>	<b>78</b>	<b>37</b>
<b>Tumor size</b>		
-<6	<b>62</b>	<b>34</b>
->6	<b>16</b>	<b>3</b>
<b>Tumor NO</b>		
-Single	<b>60</b>	<b>23</b>
-Multiple	<b>18</b>	<b>14</b>
<b>AFP</b>		
-M	<b>637.78</b>	<b>41.6</b>
-S.D	<b>1363.91</b>	<b>106.45</b>
<b>Vascular invasion</b>		
-Yes / NO	<b>14 / 64</b>	<b>3/37</b>
<b>Tumor grading</b>		
-I / II / III	<b>32 / 28/ 18</b>	<b>14/16/7</b>



# Comparison between resection & LDLT for HCC (2004 -2009 ) Mortality



	Resection	LDLT
<b>NO</b>	<b>78</b>	<b>35</b>
<b>Hospital Mortality</b>	<b>5%</b>	<b>%8</b>
<b>Flow up</b>		
– <b>M</b>	<b>17.2</b>	<b>18.67 M</b>
– <b>SD</b>	<b>12.8</b>	<b>(± 16.54)</b>
<b>Survival</b>	<b>65%</b>	<b>89%</b>
<b>Recurrence</b>	<b>39 %</b>	<b>3%</b>



# CONCLUSION



## **# Now in Egypt HCC↑ yearly**

---

- # 85 % not candid for resection**
- # The out come of resection is not satisfactory**
- # LDLT starting since 10 years in Egypt with good result up till now**
- # We are waiting for long term Flow up**

T  
H  
A  
N  
K  
K  
Y  
O  
U



T  
H  
A  
N  
K  
K  
Y  
O  
U